Lipid-Based Drug Delivery Systems in Cardiovascular Disease Treatment
Background LDD for CVD Our Services Related Products
Liposomes, nano-sized vesicles with a bilayer phospholipid membrane, have been pivotal in drug delivery research over the past three decades. Known for their biocompatibility and efficient drug encapsulation, they provide prolonged circulation and targeted delivery capabilities, making them ideal candidates for cardiovascular disease (CVD) treatment. Creative Biolabs specializes in the development of lipid-based drug delivery systems, offering a wide range of drug-loaded liposome products and customized services to help you overcome the challenges in CVD treatment.
Background of CVD Treatment
Cardiovascular Disease (CVD) is a group of diseases related to the pathological development of the heart and blood vessels, closely associated with risk factors such as cardiac metabolism, behavior, environment, and society. Nowadays, it has become one of the most significant epidemics of this century, characterized by high incidence and mortality rates, and it imposes a substantial burden of disability and medical expenses on patients. Due to the poor target specificity and low local utilization rate of drugs administered orally or systemically, patients are prone to drug induced complications such as bleeding. Therefore, achieving local controlled release drug therapy for CVD to enhance the local utilization rate of drugs and reduce systemic adverse reactions has become an urgent clinical issue that needs to be addressed.
Lipid-Based Drug Delivery Systems Applied for CVD Treatment and Diagnosis
Conventional drug therapies for CVD are fraught with various drawbacks related to their administration methods. Owing to non-specific drug delivery and a short half-life in vivo, these drugs often necessitate high concentrations for systemic administration, which may give rise to toxic side effects, drug resistance, and other issues. Liposomes, by encapsulating drugs or imaging and diagnostic agents, can achieve controlled release and extended half-life, thereby offering a promising solution for CVD treatment. By modifying liposomes with targeting agents such as antibodies, drugs can be precisely delivered to specific tissues, enhancing therapeutic efficacy through increased cellular internalization.
Throughout the progression of cardiovascular diseases, the emergence of new biomarkers and changes in tissue structure, in combination with the enhanced permeability and retention (EPR) effect at the lesion site, can be harnessed for both active and passive targeted therapies. Gaining an in-depth understanding of targets related to CVD aids in the development of antibody-modified liposomes for active targeting, which represents a significant highlight of Creative Biolabs' technological capabilities.
What We Can Do about Lipid-Based Drug Delivery Systems in CVD?
At Creative Biolabs, we specialize in developing and optimizing liposome-based therapies for cardiovascular diseases. Our services include:
-
Off-the-Shelf Liposomes: Quickly select from our catalog of pre-formulated liposomes.
-
Encapsulation Services: Efficiently encapsulate small molecules, peptides, proteins, and nucleic acids.
-
Targeted Liposomes: Develop liposomes with specific targeting ligands for precise drug delivery.
-
Imaging Liposomes: Create liposomes for real-time monitoring of drug delivery and disease progression.
-
LNP Development: Leverage our proven process for stable and effective liposome and lipid nanoparticle formulations.
Related Products
Given the urgent need for new and effective treatments for CVD, we invite you to explore the potential of liposome-based therapies with us. Contact us to learn more about our pre-formulated liposome products and customized services designed to advance CVD treatment.
For Research Use Only. Not For Clinical Use
